egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

ALISO VIEJO, Calif. – March 26, 2024 egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.

Dr. Thourani is the Bernie Marcus Chairman of the Department of Cardiovascular Surgery for Piedmont Heart Institute and Piedmont Healthcare and the Marcus Heart Valve Center, strengthening egnite’s medical advisory board with his background in cardiovascular surgery and academic research. Over Thourani’s distinguished career, he has held key leadership positions as the past-president of the Southern Thoracic Surgical Association, past-president of the Heart Valve Society, past-president of the International Society of Minimally Invasive Cardiothoracic Surgery, president-elect of the 21 Century Cardiothoracic Surgical Society, past-president of the South Atlantic Cardiovascular Surgery, and the Treasurer of the Society of Thoracic Surgeons.  He has authored over 740 peer-reviewed publications in major medical journals. Thourani’s leadership roles in prominent cardiovascular associations and research underscore his invaluable contributions to furthering egnite’s mission and the direction of its flagship solution, the CardioCare platform.

Nicholas Amoroso, MD, is an interventional cardiologist and director of the Medical University of South Carolina’s Adult Cardiac Catheterization Laboratory who brings expertise in structural heart and coronary artery disease to the advisory board. Amoroso is an emerging leader in the field, serving as an investigator for several landmark structural heart clinical trials and as a proctor for novel structural heart interventions. Amoroso’s prominent background in cardiology includes medical training at George Washington University as well as residency and fellowship programs at NYU and Mount Sinai Beth Israel. His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.

“We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board,” said Joel Portice, president and CEO of egnite. “Their collective expertise will play a pivotal role in shaping the future of digital health for cardiovascular patients. I look forward to Vinod and Nick’s partnership as we continue to develop innovative solutions in the cardiovascular community.”

The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital